Colchicine for cardiovascular disease: is UK clinical practice missing out?
Pharmaceutical Journal,
Colchicine, which is derived from the Colchicum autumnale plant, has been around for millennia, having first been recorded as a…
Colchicine, which is derived from the Colchicum autumnale plant, has been around for millennia, having first been recorded as a…
Low-dose colchicine has received approval from the US Food and Drug Administration for the prevention of cardiovascular events…
Low-dose colchicine has received approval from the US Food and Drug Administration for the prevention of cardiovascular events…
Still, a confusing rise in non-CV death merits close scrutiny in upcoming trials to inform the risk-benefit balance.
The earlier the anti-inflammatory drug colchicine is initiated after a myocardial infarction (MI) the greater the benefit, a…
1. Patients who received low-dose colchicine daily had a ~30% lower risk of cardiovascular events compared to those who…
The earlier the anti-inflammatory drug colchicine is initiated after a myocardial infarction (MI) the greater the benefit, a…
Amsterdam – Colchicin in niedriger Dosierung von 0,5 mg/Tag kann bei Patienten mit stabiler koronarer Herzkrankheit das Risiko fü…
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the…
1. Patients who received low-dose colchicine daily had a ~30% lower risk of cardiovascular events compared to those who…
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the…
Meeting Coverage > ESC LoDoCo2 trial finds substantial benefit, but questions linger Low-dose colchicine reduced cardiovascular…
On top of last year’s COLCOT results, the new findings add fuel to the inflammatory hypothesis, researchers say.
Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after recent…
Entzndliche Vorgnge spielen eine Rolle bei vielen Erkrankungen, darunter auch die Atherosklerose.
CHICAGO — Low-dose methotrexate is no better than placebo at reducing key inflammatory markers or cardiovascular (CV) events in…